Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
再生元制药公司今天宣布将于2024年8月1日美国金融市场开盘前公布2024年第二季度财务和业务结果。公司将于当天早上8:30举行电话会议和同步网络直播。
Conference Call Information
Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company's website for at least 30 days.
电话会议信息
参与者可以通过再生元网站的“投资者和媒体”页面上的网络直播收听电话会议的实况报导，网址为https://investor.regeneron.com。如需通过电话参与，请事先注册。注册后，所有电话参与者将收到一封确认电子邮件，其中详细说明如何加入电话会议，包括拨入号码以及可用于访问电话会议的唯一密码和注册者ID。电话会议和网络直播的重播和文字记录将在公司网站上归档至少30天。link。如需通过电话参与，请事先注册。注册后，所有电话参与者将收到一封确认电子邮件，其中详细说明如何加入电话会议，包括拨入号码以及可用于访问电话会议的唯一密码和注册者ID。电话会议和网络直播的重播和文字记录将在公司网站上归档至少30天。
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
关于瑞利康
再生元制药公司是一家领先的生物技术公司，专注于为患有严重疾病的人发明、开发和商业化变革性药物。我们由医学科学家创立并领导，独特的科学转化医学的能力使我们在实验室里研究开发出许多获批的治疗方案和正在研发的药物候选项。我们的药物和管线旨在帮助患者治疗眼部疾病、过敏和炎症性疾病、癌症、心血管和代谢性疾病、神经系统疾病、血液病、传染病和罕见病。
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
再生元利用其专有技术推动科学发现和药物研发，例如VelociSuite，该技术产生优化的全人类抗体和新的双重特异性抗体类。我们通过再生元遗传中心的数据驱动见解和创新的遗传医学平台，开创了医学的下一个领域，使我们能够识别创新的标靶和互补的方法，从而潜在地治疗或治愈疾病。www.Regeneron.com或关注再生元官方账号。
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
有关更多信息，请访问 www.再生元制药公司.com或关注再生元官方账号。LinkedIn, Instagram, Facebook或。X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
联系方式：
投资者关系
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
企业通讯
Christina Chan
914.847.8827
christina.chan@regeneron.com
Source: Regeneron Pharmaceuticals, Inc.
消息来源：再生元制药公司。